Trial Profile
A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Oseltamivir (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Roche
- 27 Aug 2021 Results of a efficacy exploration analysis using paediatric patients data from two studies (NV25719 and NV20234) published in the British Journal of Clinical Pharmacology
- 17 Aug 2020 Results (n=160) of PK population analysis from two clinical studies: NV20234 and NV25118 assessing pharmacologic effects of oseltamivir in immunocompromised adult patients published in the British Journal of Clinical Pharmacology
- 03 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.